Document Detail


Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
MedLine Citation:
PMID:  20601799     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pancreatic cancer represents the 4th leading cause of cancer deaths in the United States. Surgical resection remains the only potential curative approach. Current standard adjuvant therapy is gemcitabine monotherapy for 6 months. This year several trials investigated other combinations with or without molecular target agents, with or without concurrent radiation attempting to optimize adjuvant therapy. Several abstracts presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting are highlighted here and will be further discussed in this review article. Abstracts #4012, #4059, and TPS226 added immunotherapy to adjuvant treatment. Abstract #4034 demonstrated lack of efficacy by adding either cetuximab or bevacizumab to known adjuvant therapies. Abstract e14625 combined S-1 to gemcitabine and abstract #4113 demonstrated a positive correlation between symptoms and CA 19-9 levels with the length of survival.
Authors:
Jia Li; Man Yee Merl; John Chabot; Muhammad Wasif Saif
Related Documents :
21793649 - Inventors and their attorneys must beware of their actions before the us patent and tra...
22236439 - Current state of us breastfeeding laws.
19919269 - Relation of maxillary and mandibular intercuspid widths to bizygomatic and bigonial bre...
21834359 - Medicare, ethics, and reflexive longevity: governing time and treatment in an aging soc...
10755729 - What is the message of a meeting? analysis and comparison of the 2458 abstracts of the ...
7199869 - Publications resulting from anesthesia meeting abstracts.
21343629 - Quality of ethical guidelines and ethical content in clinical guidelines: the example o...
20444779 - Literature review: status and trends of research ethics in swedish nurses' dissertations.
22634569 - Tobacco industry's itga fights fctc implementation in the uruguay negotiations.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Review     Date:  2010-07-05
Journal Detail:
Title:  JOP : Journal of the pancreas     Volume:  11     ISSN:  1590-8577     ISO Abbreviation:  JOP     Publication Date:  2010  
Date Detail:
Created Date:  2010-07-05     Completed Date:  2010-11-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101091810     Medline TA:  JOP     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  310-2     Citation Subset:  IM    
Affiliation:
Yale University School of Medicine, New Haven, CT, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use
Carcinoma / therapy*
Chemotherapy, Adjuvant / methods
Chicago
Combined Modality Therapy / methods,  trends*
Congresses as Topic
Humans
Immunotherapy / methods
Medical Oncology / trends
Pancreatic Neoplasms / therapy*
Radiotherapy, Adjuvant / methods
Societies, Medical
United States
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009...
Next Document:  Updates in Locally Advanced Pancreatic Cancer. Highlights from the "2010 ASCO Annual Meeting". Chica...